Understanding resistance to combination chemotherapy

Drug Resistance Updates

Volumn 15, Issue 5-6, 2012, Pages 249-257

  Pritchard, Justin R ^a   Lauffenburger, Douglas A ^a,b   Hemann, Michael T ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Combination therapy; Cytotoxic drugs; Drug resistance; Targeted drugs

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; CAMPTOTHECIN; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; FOLIC ACID ANTAGONIST; METHOTREXATE; PREDNISONE; VASCULOTROPIN INHIBITOR; VINCRISTINE;

CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL KILLING; CHEMICAL ANALYSIS; COMPUTER MODEL; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; GENOTOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; MAMMAL CELL; MAXIMUM TOLERATED DOSE; MICROARRAY ANALYSIS; NEOPLASM; PHENOTYPE; PHYSICIAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPUTER SIMULATION; DNA DAMAGE; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 84870500959     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2012.10.003     Document Type: Review

References (76)

1. M.D. Abeloff Abeloff's Clinical Oncology 4th ed. 2008 Churchill Livingstone/Elsevier Philadelphia
2. J.S. Abramson, and M.A. Shipp Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach Blood 106 2005 1164 1174
3. P.E. Almeida Da Silva, and J.C. Palomino Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs Journal of Antimicrobial Chemotherapy 66 2011 1417 1430
4. T. Anastassiadis, S.W. Deacon, K. Devarajan, H. Ma, and J.R. Peterson Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity Nature Biotechnology 29 2011 1039 1045
5. M. Bantscheff, D. Eberhard, Y. Abraham, S. Bastuck, M. Boesche, S. Hobson, T. Mathieson, J. Perrin, M. Raida, and C. Rau Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nature Biotechnology 25 2007 1035 1044
6. M. Bantscheff, C. Hopf, M.M. Savitski, A. Dittmann, P. Grandi, A.M. Michon, J. Schlegl, Y. Abraham, I. Becher, and G. Bergamini Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes Nature Biotechnology 29 2011 255 265
7. S.R. Bartz, Z. Zhang, J. Burchard, M. Imakura, M. Martin, A. Palmieri, R. Needham, J. Guo, M. Gordon, and N. Chung Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions Molecular and Cellular Biology 26 2006 9377 9386
8. L. Beketic-Oreskovic, G.E. Duran, G. Chen, C. Dumontet, and B.I. Sikic Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833 Journal of the National Cancer Institute 87 1995 1593 1602
9. R.K. Bledsoe, V.G. Montana, T.B. Stanley, C.J. Delves, C.J. Apolito, D.D. McKee, T.G. Consler, D.J. Parks, E.L. Stewart, and T.M. Willson Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition Cell 110 2002 93 105
10. P. Borst Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biology 2 2012 120066
11. P. Borst, J. Jonkers, and S. Rottenberg What makes tumors multidrug resistant? Cell Cycle 6 2007 2782 2787
12. N. Boulos, H.L. Mulder, C.R. Calabrese, J.B. Morrison, J.E. Rehg, M.V. Relling, C.J. Sherr, and R.T. Williams Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia Blood 117 2011 3585 3595
13. M. Campillos, M. Kuhn, A.C. Gavin, L.J. Jensen, and P. Bork Drug target identification using side-effect similarity Science 321 2008 263 266
14. B.A. Chabner, and T.G. Roberts Jr. Timeline: chemotherapy and the war on cancer Nature Reviews Cancer 5 2005 65 72
15. W.W. Chen, B. Schoeberl, P.J. Jasper, M. Niepel, U.B. Nielsen, D.A. Lauffenburger, and P.K. Sorger Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data Molecular Systems Biology 5 2009 239
16. T. Conroy, F. Desseigne, M. Ychou, O. Bouche, R. Guimbaud, Y. Becouarn, A. Adenis, J.L. Raoul, S. Gourgou-Bourgade, and C. de la Fouchardiere FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer The New England Journal of Medicine 364 2011 1817 1825
17. V.T. DeVita, and P.S. Schein The use of drugs in combination for the treatment of cancer: rationale and results The New England Journal of Medicine 288 1973 998 1006
18. L. Ding, T.J. Ley, D.E. Larson, C.A. Miller, D.C. Koboldt, J.S. Welch, J.K. Ritchey, M.A. Young, T. Lamprecht, and M.D. McLellan Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing Nature 481 2012 506 510
19. J. Doles, and M.T. Hemann Nek4 status differentially alters sensitivity to distinct microtubule poisons Cancer Research 70 2010 1033 1041
20. J.T. Dudley, M. Sirota, M. Shenoy, R.K. Pai, S. Roedder, A.P. Chiang, A.A. Morgan, M.M. Sarwal, P.J. Pasricha, and A.J. Butte Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease Science Translational Medicine 3 96 2011 ra76
21. J. Durant, P. Clevenbergh, P. Halfon, P. Delgiudice, S. Porsin, P. Simonet, N. Montagne, C.A. Boucher, J.M. Schapiro, and P. Dellamonica Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial Lancet 353 1999 2195 2199
22. J.T. Erler, and R. Linding Network-based drugs and biomarkers Journal of Pathology 220 2010 290 296
23. S. Farber, and L.K. Diamond Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid The New England Journal of Medicine 238 1948 787 793
24. J.B. Fitzgerald, B. Schoeberl, U.B. Nielsen, and P.K. Sorger Systems biology and combination therapy in the quest for clinical efficacy Nature Chemical Biology 2 2006 458 466
25. E. Frei 3rd, J.F. Holland, M.A. Schneiderman, D. Pinkel, G. Selkirk, E.J. Freireich, R.T. Silver, G.L. Gold, and W. Regelson A comparative study of two regimens of combination chemotherapy in acute leukemia Blood 13 1958 1126 1148
26. E.J. Freireich, and K.M.E. Frei III Quadruple combination therapy (VAMP) for acute lymphocytic leukemia of childhood Proceedings of the American Association for Cancer Research 1964
27. L.S. Goodman, M.M. Wintrobe, W. Dameshek, M.J. Goodman, A. Gilman, and M.T. McLennan Landmark article Sept. 21, 1946: nitrogen mustard therapy L.S. Goodman, M.M. Wintrobe, W. Dameshek, M.J. Goodman, A. Gilman, M.T. McLennan, Use of Methyl-Bis(Beta-Chloroethyl)Amine Hydrochloride and Tris(Beta-Chloroethyl) Amine Hydrochloride for Hodgkin's Disease, Lymphosarcoma, Leukemia and Certain Allied and Miscellaneous Disorders vol. 251 1984 2255 2261 Jama
28. M.W. Hashimoto, O. Nikaido, N. Kobayashi, C.C. Chang, J.E. Trosko, and T. Mori A comparison of the propensity for gene amplification between near-tetraploid and near-diploid V79 clones resistant to 150 nM methotrexate Carcinogenesis 17 1996 389 394
29. H. Hieronymus, J. Lamb, K.N. Ross, X.P. Peng, C. Clement, A. Rodina, M. Nieto, J. Du, K. Stegmaier, and S.M. Raj Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators Cancer Cell 10 2006 321 330
30. K.A. Janes, J.G. Albeck, S. Gaudet, P.K. Sorger, D.A. Lauffenburger, and M.B. Yaffe A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis Science 310 2005 1646 1653
31. K.A. Janes, J.R. Kelly, S. Gaudet, J.G. Albeck, P.K. Sorger, and D.A. Lauffenburger Cue-signal-response analysis of TNF-induced apoptosis by partial least squares regression of dynamic multivariate data Journal of Computational Biology 11 2004 544 561
32. H. Jiang, J.R. Pritchard, R.T. Williams, D.A. Lauffenburger, and M.T. Hemann A mammalian functional-genetic approach to characterizing cancer therapeutics Nature Chemical Biology 7 2011 92 100
33. H.M. Kantarjian, N.P. Shah, J.E. Cortes, M. Baccarani, M.B. Agarwal, M.S. Undurraga, J. Wang, J.J. Ipina, D.W. Kim, and M. Ogura Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) Blood 119 2012 1123 1129
34. M.W. Karaman, S. Herrgard, D.K. Treiber, P. Gallant, C.E. Atteridge, B.T. Campbell, K.W. Chan, P. Ciceri, M.I. Davis, and P.T. Edeen A quantitative analysis of kinase inhibitor selectivity Nature Biotechnology 26 2008 127 132
35. P.K. Kreeger, and D.A. Lauffenburger Cancer systems biology: a network modeling perspective Carcinogenesis 31 2010 2 8
36. P.K. Kreeger, R. Mandhana, S.K. Alford, K.M. Haigis, and D.A. Lauffenburger RAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma cells via ERK-modulatory negative and positive feedback circuits along with non-ERK pathway effects Cancer Research 69 2009 8191 8199
37. N. Kumar, R. Afeyan, H.D. Kim, and D.A. Lauffenburger Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells Molecular Pharmacology 73 2008 1668 1678
38. J. Lamb, E.D. Crawford, D. Peck, J.W. Modell, I.C. Blat, M.J. Wrobel, J. Lerner, J.P. Brunet, A. Subramanian, and K.N. Ross The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease Science 313 2006 1929 1935
39. L.W. Law Effects of combinations of antileukemic agents on an acute lymphocytic leukemia of mice Cancer Research 12 1952 871 878
40. L.W. Law Origin of the resistance of leukaemic cells to folic acid antagonists Nature 169 1952 628 629
41. J.K. Lee, D.M. Havaleshko, H. Cho, J.N. Weinstein, E.P. Kaldjian, J. Karpovich, A. Grimshaw, and D. Theodorescu A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery Proceedings of the National Academy of Sciences of the United States of America 104 2007 13086 13091
42. A.G. Letai Diagnosing and exploiting cancer's addiction to blocks in apoptosis Nature Reviews Cancer 8 2008 121 132
43. S.E. Luria, and M. Delbruck Mutations of bacteria from virus sensitivity to virus resistance Genetics 28 1943 491 511
44. D.A. Matthews, R.A. Alden, J.T. Bolin, S.T. Freer, R. Hamlin, N. Xuong, J. Kraut, M. Poe, M. Williams, and K. Hoogsteen Dihydrofolate reductase: X-ray structure of the binary complex with methotrexate Science 197 1977 452 455
45. K. Miller-Jensen, K.A. Janes, J.S. Brugge, and D.A. Lauffenburger Common effector processing mediates cell-specific responses to stimuli Nature 448 2007 604 608
46. C.G. Mullighan, L.A. Phillips, X. Su, J. Ma, C.B. Miller, S.A. Shurtleff, and J.R. Downing Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia Science 322 2008 1377 1380
47. C.G. Mullighan, J. Zhang, L.H. Kasper, S. Lerach, D. Payne-Turner, L.A. Phillips, S.L. Heatley, L. Holmfeldt, J.R. Collins-Underwood, and J. Ma CREBBP mutations in relapsed acute lymphoblastic leukaemia Nature 471 2011 235 239
48. H.B. Newcombe, and R. Hawirko Spontaneous mutation to streptomycin resistance and dependence in Escherichia coli Journal of Bacteriology 57 1949 565 572
49. T. Ni Chonghaile, K.A. Sarosiek, T.T. Vo, J.A. Ryan, A. Tammareddi, G. Moore Vdel, J. Deng, K.C. Anderson, P. Richardson, and Y.T. Tai Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy Science 334 2011 1129 1133
50. K.D. Paull, R.H. Shoemaker, L. Hodes, A. Monks, D.A. Scudiero, L. Rubinstein, J. Plowman, and M.R. Boyd Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm Journal of the National Cancer Institute 81 1989 1088 1092
51. T. Pawson, and R. Linding Network medicine FEBS Letters 582 2008 1266 1270
52. R. Pirker, J.R. Pereira, A. Szczesna, J. von Pawel, M. Krzakowski, R. Ramlau, I. Vynnychenko, K. Park, C.T. Yu, and V. Ganul Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 2009 1525 1531
53. Y. Pommier, E. Leo, H. Zhang, and C. Marchand DNA topoisomerases and their poisoning by anticancer and antibacterial drugs Chemistry and Biology 17 2010 421 433
54. U. Scherf, D.T. Ross, M. Waltham, L.H. Smith, J.K. Lee, L. Tanabe, K.W. Kohn, W.C. Reinhold, T.G. Myers, and D.T. Andrews A gene expression database for the molecular pharmacology of cancer Nature Genetics 24 2000 236 244
55. B. Schoeberl, E.A. Pace, J.B. Fitzgerald, B.D. Harms, L. Xu, L. Nie, B. Linggi, A. Kalra, V. Paragas, and R. Bukhalid Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis Science Signaling 2 2009 ra31
56. N.P. Shah, B.J. Skaggs, S. Branford, T.P. Hughes, J.M. Nicoll, R.L. Paquette, and C.L. Sawyers Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency The Journal of Clinical Investigation 117 2007 2562 2569
57. N.P. Shah, C. Tran, F.Y. Lee, P. Chen, D. Norris, and C.L. Sawyers Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 2004 399 401
58. M. Sirota, J.T. Dudley, J. Kim, A.P. Chiang, A.A. Morgan, A. Sweet-Cordero, J. Sage, and A.J. Butte Discovery and preclinical validation of drug indications using compendia of public gene expression data Science Translational Medicine 3 96 2011 ra77
59. H.E. Skipper, F.M. Schabel Jr., and W.S. Wilcox Experimental evaluation of potential anticancer agents, Xiii. On the criteria and kinetics associated with "curability" of experimental leukemia Cancer Chemotherapy Reports. Part 1 35 1964 1 111
60. H.E. Skipper, J.R. Thomson, and M. Bell Attempts at dual blocking of biochemical events in cancer chemotherapy Cancer Research 14 1954 503 507
61. B.L. Staker, K. Hjerrild, M.D. Feese, C.A. Behnke, A.B. Burgin Jr., and L. Stewart The mechanism of topoisomerase I poisoning by a camptothecin analog Proceedings of the National Academy of Sciences of the United States of America 99 2002 15387 15392
62. G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nature Reviews Drug Discovery 5 2006 219 234
63. M. Talpaz, N.P. Shah, H. Kantarjian, N. Donato, J. Nicoll, R. Paquette, J. Cortes, S. O'Brien, C. Nicaise, and E. Bleickardt Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias The New England Journal of Medicine 354 2006 2531 2541
64. A.R. Tentner, M.J. Lee, G.J. Ostheimer, L.D. Samson, D.A. Lauffenburger, and M.B. Yaffe Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress Molecular Systems Biology 8 2012 568
65. J.E. Toettcher, A. Loewer, G.J. Ostheimer, M.B. Yaffe, B. Tidor, and G. Lahav Distinct mechanisms act in concert to mediate cell cycle arrest Proceedings of the National Academy of Sciences of the United States of America 106 2009 785 790
66. A.B. Turke, K. Zejnullahu, Y.L. Wu, Y. Song, D. Dias-Santagata, E. Lifshits, L. Toschi, A. Rogers, T. Mok, and L. Sequist Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC Cancer Cell 17 2010 77 88
67. N. Wagle, C. Emery, M.F. Berger, M.J. Davis, A. Sawyer, P. Pochanard, S.M. Kehoe, C.M. Johannessen, L.E. Macconaill, and W.C. Hahn Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 29 2011 3085 3096
68. M.E. Wall, and M.C. Wani Camptothecin and taxol: discovery to clinic-thirteenth Bruce F. Cain Memorial Award Lecture Cancer Research 55 1995 753 760
69. G. Wei, D. Twomey, J. Lamb, K. Schlis, J. Agarwal, R.W. Stam, J.T. Opferman, S.E. Sallan, M.L. den Boer, and R. Pieters Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance Cancer Cell 10 2006 331 342
70. J.N. Weinstein, T.G. Myers, P.M. O'Connor, S.H. Friend, A.J. Fornace Jr., K.W. Kohn, T. Fojo, S.E. Bates, L.V. Rubinstein, and N.L. Anderson An information-intensive approach to the molecular pharmacology of cancer Science 275 1997 343 349
71. A.W. Whitehurst, B.O. Bodemann, J. Cardenas, D. Ferguson, L. Girard, M. Peyton, J.D. Minna, C. Michnoff, W. Hao, and M.G. Roth Synthetic lethal screen identification of chemosensitizer loci in cancer cells Nature 446 2007 815 819
72. A.J. Wolpaw, K. Shimada, R. Skouta, M.E. Welsch, U.D. Akavia, D. Pe'er, F. Shaik, J.C. Bulinski, and B.R. Stockwell Modulatory profiling identifies mechanisms of small molecule-induced cell death Proceedings of the National Academy of Sciences of the United States of America 108 2011 E771 E780
73. L. Xie, S.L. Kinnings, and P.E. Bourne Novel computational approaches to polypharmacology as a means to define responses to individual drugs Annual Review of Pharmacology and Toxicology 52 2012 361 379
74. R.L. Yauch, G.J. Dijkgraaf, B. Alicke, T. Januario, C.P. Ahn, T. Holcomb, K. Pujara, J. Stinson, C.A. Callahan, and T. Tang Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma Science 326 2009 572 574
75. S.A. Zander, A. Kersbergen, E. van der Burg, N. de Water, O. van Tellingen, S. Gunnarsdottir, J.E. Jaspers, M. Pajic, A.O. Nygren, and J. Jonkers Sensitivity and acquired resistance of BRCA1; p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan Cancer Research 70 2010 1700 1710
76. J. Zhang, F.J. Adrian, W. Jahnke, S.W. Cowan-Jacob, A.G. Li, R.E. Iacob, T. Sim, J. Powers, C. Dierks, and F. Sun Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors Nature 463 2010 501 506